New drug combo aims to shrink tough thymus tumors before surgeons operate
NCT ID NCT01025089
Summary
This study tested whether adding the drug cetuximab to standard chemotherapy could better shrink advanced thymoma or thymic carcinoma tumors before surgery. It involved 18 patients with these rare cancers that had not spread to distant organs. The goal was to see if this combination could completely eliminate the cancer in the removed tissue and make surgery more successful.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010-3000, United States
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center
Sleepy Hollow, New York, 10591, United States
-
Memorial Sloan Kettering West Harrison
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
Conditions
Explore the condition pages connected to this study.